These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 19594728)

  • 1. Post-trial access to antiretrovirals: who owes what to whom?
    Millum J
    Bioethics; 2011 Mar; 25(3):145-54. PubMed ID: 19594728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mind the gap: An empirical study of post-trial access in HIV biomedical prevention trials.
    Haire B; Jordens C
    Dev World Bioeth; 2015 Aug; 15(2):85-97. PubMed ID: 26193849
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The obligation to provide antiretroviral treatment in HIV prevention trials.
    Lo B; Padian N; Barnes M
    AIDS; 2007 Jun; 21(10):1229-31. PubMed ID: 17545698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reciprocity and post-trial access for participants in antiretroviral therapy trials.
    Merritt M; Grady C
    AIDS; 2006 Sep; 20(14):1791-4. PubMed ID: 16954719
    [No Abstract]   [Full Text] [Related]  

  • 5. Access to treatment in HIV prevention trials: perspectives from a South African community.
    Barsdorf N; Maman S; Kass N; Slack C
    Dev World Bioeth; 2010 Aug; 10(2):78-87. PubMed ID: 19793135
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Creation of a drug fund for post-clinical trial access to antiretrovirals.
    Ananworanich J; Cheunyam T; Teeratakulpisarn S; Boyd MA; Ruxrungtham K; Lange J; Cooper D; Phanuphak P
    Lancet; 2004 Jul 3-9; 364(9428):101-2. PubMed ID: 15234863
    [No Abstract]   [Full Text] [Related]  

  • 7. Equitable treatment for HIV/AIDS clinical trial participants: a focus group study of patients, clinician researchers, and administrators in Western Kenya.
    Shaffer DN; Yebei VN; Ballidawa JB; Sidle JE; Greene JY; Meslin EM; Kimaiyo SJ; Tierney WM
    J Med Ethics; 2006 Jan; 32(1):55-60. PubMed ID: 16373525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subjects' views of obligations to ensure post-trial access to drugs, care and information: qualitative results from the Experiences of Participants in Clinical Trials (EPIC) study.
    Sofaer N; Thiessen C; Goold SD; Ballou J; Getz KA; Koski G; Krueger RA; Weissman JS
    J Med Ethics; 2009 Mar; 35(3):183-8. PubMed ID: 19251971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Provision of HIV treatment in HIV preventive vaccine trials: a developing country perspective.
    Slack C; Stobie M; Milford C; Lindegger G; Wassenaar D; Strode A; Ijsselmuiden C
    Soc Sci Med; 2005 Mar; 60(6):1197-208. PubMed ID: 15626517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV vaccine trials: reconsidering the therapeutic misconception and the question of what constitutes trial related injuries.
    Schüklenk U; Ashcroft R
    Dev World Bioeth; 2007 Dec; 7(3):ii-iv. PubMed ID: 18021115
    [No Abstract]   [Full Text] [Related]  

  • 11. Standards of care in the antiretroviral rollout world.
    Singh JA
    Lancet; 2004 Sep 11-17; 364(9438):920-2. PubMed ID: 15364176
    [No Abstract]   [Full Text] [Related]  

  • 12. Standard of care for HIV prevention technology research: a consensus document from Nigeria.
    Folayan MO; Falobi O; Faleyimu B; Ogunlayi M
    Afr J Med Med Sci; 2011 Sep; 40(3):265-71. PubMed ID: 22428522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Because we can: clashes of perspective over researcher obligation in the failed PrEP trials.
    Haire BG
    Dev World Bioeth; 2011 Aug; 11(2):63-74. PubMed ID: 21266000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Role of Community Engagement in Novel HIV Research in Infants.
    Shah SK; Wilfond BS
    Perspect Biol Med; 2016; 58(3):344-7. PubMed ID: 27157353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Post-trial access to tested interventions: the views of IRB/REC chair, investigators, and research participants in a multinational HIV/AIDS study.
    Pace C; Grady C; Wendler D; Bebchuk JD; Tavel JA; McNay LA; Forster HP; Killen J; Emanuel EJ
    AIDS Res Hum Retroviruses; 2006 Sep; 22(9):837-41. PubMed ID: 16989607
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The challenge of defining standards of prevention in HIV prevention trials.
    Philpott S; Heise L; McGrory E; Paxton L; Hankins C;
    J Med Ethics; 2011 Apr; 37(4):244-8. PubMed ID: 21186207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The balm of Gilead: is the provision of treatment to those who seroconvert in HIV prevention trials a matter of moral obligation or moral negotiation?
    Weijer C; Leblanc GJ
    J Law Med Ethics; 2006; 34(4):793-808. PubMed ID: 17199821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV international clinical research: exploitation and risk.
    Ballantyne A
    Bioethics; 2005 Oct; 19(5-6):476-91. PubMed ID: 16425485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Practice of Pharmaceutics and the Obligation to Expand Access to Investigational Drugs.
    Buckley M; O'neil C
    J Med Philos; 2020 Mar; 45(2):193-211. PubMed ID: 31885051
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of activists in access to HIV and tuberculosis treatment and prevention.
    Geffen N
    Curr Opin HIV AIDS; 2017 Jul; 12(4):398-402. PubMed ID: 28463853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.